Lighthouse Church's Keion Henderson is excited about the practical potential of a technology that many are wary of and wants ...

5 analysts have shared their evaluations of Legend Biotech LEGN during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ...

5 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their ...

Legend Biotech Corporation (NASDAQ:LEGN), a $6.8 billion biotechnology company focused on developing novel cell therapies for oncology and other indications, has been garnering significant ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price dropped by analysts at Morgan Stanley from $82.00 to ...

Caroline Paul; Associate Director of Investor Relations; Nanjing Legend Biotechnology Co Ltd Ying Huang; Chief Executive Officer; Nanjing Legend Biotechnology Co Ltd Jessie Yeung; Interim Chief ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Legend Biotech (LEGN – Research Report) and ...

Legend Biotech Corporation Sponsored ADR (LEGN) reported $186.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 134.7%. EPS of -$0.15 for the ...

Legend Biotech Corporation (NASDAQ:LEGN), a $6.8 billion biotechnology company focused on developing novel cell therapies for oncology and other indications, has been garnering significant attention ...